Literature DB >> 30606659

miR-23a-3p suppresses cell proliferation in oral squamous cell carcinomas by targeting FGF2 and correlates with a better prognosis: miR-23a-3p inhibits OSCC growth by targeting FGF2.

Fubo Chen1, Shengcai Qi1, Xu Zhang1, Jinjin Wu1, Xi Yang2, Raorao Wang3.   

Abstract

Oral squamous cell carcinomas (OSCCs) are one of the most ubiquitous malignancies the world over, and are accompanied by a high mortality. microRNAs (miRNAs) have increasingly garnered attention with regards to the roles they play in initiation and progression of various kinds of cancers, including OSCC. It has been reported, that miR-23a-3p promotes the development of tumors for prostate cancer, gastric cancer and gliomas. The functions of miR-23a-3p in OSCC however, remain unclear. In this study, fibroblast growth factor 2 (FGF2) is revealed as a direct target of miR-23a-3p, based on luciferase assays and immunoblotting. The expression of miR-23a-3p and FGF2 were found to be significantly downregulated and upregulated in OSCC tissues respectively. This indicates a reverse correlation between miR-23a-3p and FGF2 levels. Using in vitro approaches we ascertained that miR-23a-3p might contribute to the inhibition of growth and inhibition through increasing apoptosis in OSCC cells; while an inhibitor of miR-23a-3p could reverse this effect. Examination of a clinical cohort of OSCC patients suggested that reduced expression of miR-23a-3p is correlated with more advanced cancerous stage and poorer differentiation of OSCC cell. Additionally, a survival analysis and the Cox-hazard regression model showed that higher levels of miR-23a-3p can be used reliably for prognosis of OSCC patients. This study indicates that miR-23a-3p might suppress tumor proliferation, invasion and promote apoptosis of OSCC by targeting FGF2. miR-23a-3p has the potential to be used as prognostic indicator, and could be exploited as a therapeutic reagent for OSCC in the future.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  FGF2; OSCC; Prognosis; miR-23a-3p

Mesh:

Substances:

Year:  2018        PMID: 30606659     DOI: 10.1016/j.prp.2018.12.021

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  18 in total

1.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022

2.  Hsa-miRNA-23a-3p promotes atherogenesis in a novel mouse model of atherosclerosis.

Authors:  Jiayan Guo; Hanbing Mei; Zhen Sheng; Qingyuan Meng; Murielle M Véniant; Hong Yin
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

3.  HP1BP3 promotes tumor growth and metastasis by upregulating miR-23a to target TRAF5 in esophageal squamous cell carcinoma.

Authors:  Mingyi Shang; Li Weng; Shaoqiu Wu; Bingyan Liu; Xiang Yin; Zhongmin Wang; Aiwu Mao
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  miR-23a-3p inhibits sepsis-induced kidney epithelial cell injury by suppressing Wnt/β-catenin signaling by targeting wnt5a.

Authors:  Junwei Ye; Huibing Feng; Zhiyong Peng
Journal:  Braz J Med Biol Res       Date:  2022-02-28       Impact factor: 2.590

5.  Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome.

Authors:  Siri H Strand; Linnéa Schmidt; Simone Weiss; Michael Borre; Helle Kristensen; Anne Karin Ildor Rasmussen; Tina Fuglsang Daugaard; Gitte Kristensen; Hein Vincent Stroomberg; Martin Andreas Røder; Klaus Brasso; Peter Mouritzen; Karina Dalsgaard Sørensen
Journal:  Sci Rep       Date:  2020-07-01       Impact factor: 4.379

6.  NEAT1/miR-23a-3p/KLF3: a novel regulatory axis in melanoma cancer progression.

Authors:  Fei Ding; Jindong Lai; Yang Gao; Genhui Wang; Jingwen Shang; Daojun Zhang; Shumao Zheng
Journal:  Cancer Cell Int       Date:  2019-08-22       Impact factor: 5.722

Review 7.  Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

Authors:  Surojit Paul; Eduardo Candelario-Jalil
Journal:  Exp Neurol       Date:  2020-11-02       Impact factor: 5.330

8.  Lack of Conserved miRNA Deregulation in HPV-Induced Squamous Cell Carcinomas.

Authors:  Jaroslav Nunvar; Lucie Pagacova; Zuzana Vojtechova; Nayara Trevisan Doimo de Azevedo; Jana Smahelova; Martina Salakova; Ruth Tachezy
Journal:  Biomolecules       Date:  2021-05-20

9.  Insight into the effects of microRNA-23a-3p on pancreatic cancer and its underlying molecular mechanism.

Authors:  Jiadeng Chao; Lei Jin; Xudong Zhang; Dong Ding; Siyuan Wu; Le Ma; Bei Zhu; Shiting Shan; Xiao Yun; Peng Gao; Jun Li; Chunfu Zhu; Xihu Qin
Journal:  Oncol Lett       Date:  2019-11-19       Impact factor: 2.967

10.  TMEM161B-AS1 suppresses proliferation, invasion and glycolysis by targeting miR-23a-3p/HIF1AN signal axis in oesophageal squamous cell carcinoma.

Authors:  Zuxuan Shi; Guanghui Li; Zhen Li; Junhao Liu; Yu Tang
Journal:  J Cell Mol Med       Date:  2021-05-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.